ThromboGenics NV has announced that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA® is listed in the ...

Please provide your email address to receive an email when new articles are posted on . ThromboGenics announced positive topline results from the OASIS study of Jetrea in patients with symptomatic ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ocriplasmin (Jetrea, Thrombogenics, NV) for the treatment of adults with ...

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced that the UK’s National Institute for Health and Care Excellence (NICE ...

BRUSSELS (Reuters) – Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second half of ...

Leuven, March 16, 2015 - ThromboGenics NV (Euronext Brussels:THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces ...

Please provide your email address to receive an email when new articles are posted on . ThromboGenics has started to evaluate Jetrea as a potential treatment for retinal vein occlusion, according to a ...

ThromboGenics NV has announced that the European Commission has approved JETREA® (ocriplasmin) in the European Union. JETREA® is approved for the treatment of vitreomacular traction (VMT), including ...

NICE today has issued final draft guidance that recommends ocriplasmin (Jetrea, manufactured by ThromboGenics) as a treatment option for some adults with vitreomacular traction. Ocriplasmin has been ...

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has ...